# US 2010/0168058 A1 · Novel antagonists of the toll-like receptor 4

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168058 A1
- Document ID: US20100168058A1
- Status: Published application
- Kind: A1
- Application number: 12/443,681
- Filed: 2006-10-02
- Published: 2010-07-01
- Earliest claimed: 2006-10-02
- Inventors: Leonardus Antonius B. JOOSTEN
- Web page: https://patentgrep.com/patent/US20100168058A1

## CPC

- A61K 31/739: Lipopolysaccharides
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a novel antagonist of the Toll-like receptor 4 (TLR-4). More specifically, the present invention relates to a lipopolysaccharide (LPS) isolated from the bacterium Bartonella quintana as a novel antagonist of the Toll-like receptor 4 (TLR-4). Further, the present invention relates to the use of said natural antagonist for the treatment of an autoimmune or inflammatory disease in a mammal and specifically for the treatment of rheumatoid arthritis (RA). Furthermore, the present invention relates to pharmaceutical compositions comprising a lipopolysaccharide (LPS) isolated from the bacterium Bartonella quintana.

## Claims

### Claim 1

Use of Bartonella quintana lipopolysaccharide or a functional equivalent fragment thereof for the preparation of a medicament for the treatment of an autoimmune disease, an autoinflammatory disease, or an infectious disease in a mammal.

### Claim 2 (depends on 1)

Use according to claim 1, wherein the mammal is a human mammal.

### Claim 3 (depends on 2)

Use according to claim 2, wherein the treatment comprises inhibition of the toll-like receptor signaling.

### Claim 4 (depends on 1)

Use according to claim 1, wherein the treatment comprises inhibition of the toll-like receptor 4 (TLR-4)

### Claim 5 (depends on 1)

Use according to claim 1, wherein the autoimmune or inflammatory disease is selected from the group consisting of rheumatoid arthritis, Crohn's disease, bacterial, viral and fungal infections, bacterial, viral and fungal infections resulting in secondary side-effects, SIRS, sepsis, atherosclerosis, type I diabetes mellitus, Wegener's granulomatosis, ulcerative colitis, systemic lupus erythemotosis (SLE), psoriasis, and multiple sclerosis.

### Claim 6 (depends on 5)

Use according to claim 5, wherein the autoimmune disease is rheumatoid arthritis.

### Claim 7

Bartonella quintana lipopolysaccharide or a functional equivalent fragment thereof for use as a medicament.

### Claim 8

Medicament comprising Bartonella quintana lipopolysaccharide or a functional equivalent fragment thereof and one or more pharmaceutically acceptable excipients and/or carriers.

### Claim 9

Method for treating an autoimmune or inflammatory disease comprising administering an therapeutic amount of Bartonella quintana lipopolysaccharide or a functional equivalent fragment thereof to a mammal suffering from an autoimmune, an autoinflammatory, or an infectious disease.

### Claim 10 (depends on 9)

Method according to claim 9, wherein the mammal is a human mammal.

### Claim 11

Use of a Toll-like 4 receptor (TLR-4) antagonist for the preparation of a medicament for the treatment of rheumatoid arthritis.

### Claim 12 (depends on 11)

Use according to claim 11, wherein the Toll-like 4 receptor (TLR-4) antagonist is Bartonella quintana lipopolysaccharide (LPS) or a functional equivalent thereof.
